Sanofi: Number of Employees 2012-2026 | SNY
Interactive chart of Sanofi (SNY) annual worldwide employee count from 2012 to 2026.
- Sanofi total number of employees in 2025 was 74,846, a 9.69% decline from 2024.
- Sanofi total number of employees in 2024 was 82,878, a 3.73% decline from 2023.
- Sanofi total number of employees in 2023 was 86,088, a 5.99% decline from 2022.
- Sanofi total number of employees in 2022 was 91,573, a 4.05% decline from 2021.
| Sanofi Annual Employee Count | |
|---|---|
| 2025 | 74,846 |
| 2024 | 82,878 |
| 2023 | 86,088 |
| 2022 | 91,573 |
| 2021 | 95,442 |
| 2020 | 99,412 |
| 2019 | 100,409 |
| 2018 | 104,226 |
| 2017 | 106,566 |
| 2016 | 106,859 |
| 2015 | 115,631 |
| 2014 | 113,496 |
| 2013 | 112,128 |
| 2012 | 111,974 |
| 2011 | 113,719 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $105.050B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |